New NLITE(TM) Laser Collagen Replenishment (LCR) System Study Data to Be Presented at Upcoming American Society for Laser Medicine & Surgery (ASLMS) Annual Meeting

Apr 19, 2001, 01:00 ET from ICN Pharmaceuticals, Inc.

    COSTA MESA, Calif., April 19 /PRNewswire/ -- ICN Pharmaceuticals, Inc.
 (NYSE:   ICN), said today that scientific presentations regarding the company's
 recently FDA cleared NLITE(TM) Laser Collagen Replenishment system will be
 made at the American Society for Laser Medicine and Surgery Annual Meeting
 April 20 - 22, 2001 at the Hyatt Regency New Orleans, Louisiana.
     Four presentations will be given covering various aspects of the NLITE(TM)
 LCR procedure.  These presentations, reviewing clinical and scientific
 studies, include:  "Biochemical Analysis of Type III Skin Collagen Production
 Rate During Non-Ablative Wrinkle Reduction" on Friday, April 20th, "Novel Non-
 Ablative Cutaneous Laser Applications" on Saturday, April 21st and "Non-
 Ablative Wrinkle Reduction, A Prospective Study of Efficacy and Side Effects"
 on Sunday, April 22nd.
     NLITE(TM) Non-ablative laser is a revolutionary breakthrough in lasers
 offering physicians and patients a safe, confidential system for periocular
 wrinkle removal with no down time, and without causing significant superficial
 skin damage.
     The ASLMS is the largest organization of its kind seeking to enhance
 dialogue between clinicians, scientists, industry and government through its
 variety of educational formats.  It is dedicated to enhancing the
 understanding of lasers and the application of lasers and related technologies
 in biomedicine.  The annual meeting of the ASLMS enables experts within the
 field to gather, present and share the latest information regarding biomedical
 applications of laser technologies.
     Among its dermatological product portfolio, ICN manufactures and markets
 Efudex(R) (fluorouracil) for the indication of actinic keratosis (a
 precancerous skin condition), Kinerase(TM) (N6-furfuryladenine) wrinkle-
 reduction cream, Glyquin(R) (4% hydroquinone with 10% glycolic acid) for the
 treatment of hyperpigmentation, the Gly-derm(TM) line of cosmeceuticals,
 Solaquin Forte(R) for hyperpigmentation Oxsoralen(R) for severe psoriasis,
 used by dermatologists in conjunction with ultraviolet light, and the
 Rejuvasilk(TM) and Microglide(TM) Micro-dermabrasion systems.
     ICN manufactures, markets and distributes a broad range of prescription
 and non-prescription pharmaceuticals, including anti-infectives, anti-virals,
 and anti-cancer drugs, under the ICN brand name.
     Additional information is also available on the corporate website at
 http://www.icnpharm.com and the NLITE LCR(TM) website at
 http://www.wrinklereduction.com.   Additional information about the ASLMS can
 be found at www.aslms.org.
     THE 'SAFE HARBOR' STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM
 ACT OF 1995.  This press release contains forward-looking statements that
 involve risks and uncertainties including, but not limited to, projections of
 future sales, operating income, subsidiary reorganization, regulatory approval
 processes, operations in countries with unstable economies, the progress of
 FDA reviews, and other risks detailed from time to time in the Company's
 Securities and Exchange Commission filings.
 
 

SOURCE ICN Pharmaceuticals, Inc.
    COSTA MESA, Calif., April 19 /PRNewswire/ -- ICN Pharmaceuticals, Inc.
 (NYSE:   ICN), said today that scientific presentations regarding the company's
 recently FDA cleared NLITE(TM) Laser Collagen Replenishment system will be
 made at the American Society for Laser Medicine and Surgery Annual Meeting
 April 20 - 22, 2001 at the Hyatt Regency New Orleans, Louisiana.
     Four presentations will be given covering various aspects of the NLITE(TM)
 LCR procedure.  These presentations, reviewing clinical and scientific
 studies, include:  "Biochemical Analysis of Type III Skin Collagen Production
 Rate During Non-Ablative Wrinkle Reduction" on Friday, April 20th, "Novel Non-
 Ablative Cutaneous Laser Applications" on Saturday, April 21st and "Non-
 Ablative Wrinkle Reduction, A Prospective Study of Efficacy and Side Effects"
 on Sunday, April 22nd.
     NLITE(TM) Non-ablative laser is a revolutionary breakthrough in lasers
 offering physicians and patients a safe, confidential system for periocular
 wrinkle removal with no down time, and without causing significant superficial
 skin damage.
     The ASLMS is the largest organization of its kind seeking to enhance
 dialogue between clinicians, scientists, industry and government through its
 variety of educational formats.  It is dedicated to enhancing the
 understanding of lasers and the application of lasers and related technologies
 in biomedicine.  The annual meeting of the ASLMS enables experts within the
 field to gather, present and share the latest information regarding biomedical
 applications of laser technologies.
     Among its dermatological product portfolio, ICN manufactures and markets
 Efudex(R) (fluorouracil) for the indication of actinic keratosis (a
 precancerous skin condition), Kinerase(TM) (N6-furfuryladenine) wrinkle-
 reduction cream, Glyquin(R) (4% hydroquinone with 10% glycolic acid) for the
 treatment of hyperpigmentation, the Gly-derm(TM) line of cosmeceuticals,
 Solaquin Forte(R) for hyperpigmentation Oxsoralen(R) for severe psoriasis,
 used by dermatologists in conjunction with ultraviolet light, and the
 Rejuvasilk(TM) and Microglide(TM) Micro-dermabrasion systems.
     ICN manufactures, markets and distributes a broad range of prescription
 and non-prescription pharmaceuticals, including anti-infectives, anti-virals,
 and anti-cancer drugs, under the ICN brand name.
     Additional information is also available on the corporate website at
 http://www.icnpharm.com and the NLITE LCR(TM) website at
 http://www.wrinklereduction.com.   Additional information about the ASLMS can
 be found at www.aslms.org.
     THE 'SAFE HARBOR' STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM
 ACT OF 1995.  This press release contains forward-looking statements that
 involve risks and uncertainties including, but not limited to, projections of
 future sales, operating income, subsidiary reorganization, regulatory approval
 processes, operations in countries with unstable economies, the progress of
 FDA reviews, and other risks detailed from time to time in the Company's
 Securities and Exchange Commission filings.
 
 SOURCE  ICN Pharmaceuticals, Inc.